Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children vaccinated at 12–23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A–specific IgG enzyme-linked immunosorbent assay (ELISA). Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination. Clinical Trials Registration. ISRTCN78147026.

[1]  R. Adegbola,et al.  Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Hugonnet,et al.  Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study , 2013, The Lancet.

[3]  N. Klein,et al.  One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children , 2013, The Pediatric infectious disease journal.

[4]  T. Vesikari,et al.  Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers , 2012, Human vaccines & immunotherapeutics.

[5]  Ryan T Novak,et al.  Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. , 2012, Vaccine.

[6]  C. Frasch,et al.  Development of a group A meningococcal conjugate vaccine, MenAfriVacTM , 2012, Human vaccines & immunotherapeutics.

[7]  D. Diop,et al.  Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. , 2011, The New England journal of medicine.

[8]  N. Andrews,et al.  Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine , 2009, Clinical and Vaccine Immunology.

[9]  N. Ravenscroft,et al.  Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. , 2009, Vaccine.

[10]  The immunological basis for immunization series Module , 2009 .

[11]  G. Tzanakaki,et al.  Conjugate vaccine-induced immunological priming is not protective against acute meningococcal C infection. , 2007, Vaccine.

[12]  M. Préziosi,et al.  The Meningitis Vaccine Project. , 2007, Vaccine.

[13]  N. Andrews,et al.  Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. , 2006, The Journal of infectious diseases.

[14]  E. Miller,et al.  Long-term protection in children with meningococcal C conjugate vaccination: lessons learned , 2006, Expert review of vaccines.

[15]  D. Granoff,et al.  Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries , 2003, The Lancet.

[16]  N. Andrews,et al.  Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. , 2002, The Journal of infectious diseases.

[17]  N. Begg,et al.  Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine , 2000, Epidemiology and Infection.

[18]  G. Carlone,et al.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group , 1997, Clinical and diagnostic laboratory immunology.

[19]  G. Carlone,et al.  Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays , 1997 .

[20]  B. Plikaytis,et al.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992 , 1995, Clinical and diagnostic laboratory immunology.

[21]  B. Plikaytis,et al.  Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay , 1992, Journal of clinical microbiology.